Published in Oncotarget on November 04, 2016
Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer. Front Oncol (2017) 0.75
Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol (2003) 15.65
Vascular endothelial growth factor (VEGF) and its receptors. FASEB J (1999) 10.09
Current concepts of the immunological function of the thymus. Physiol Rev (1967) 8.37
Positive and negative selection of T cells. Annu Rev Immunol (2002) 8.32
Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol (2001) 6.30
Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med (1993) 4.04
Immune therapy for cancer. Annu Rev Immunol (2009) 3.71
The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol (1998) 3.68
Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev (2002) 2.86
Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol (1994) 2.68
The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell (2006) 2.13
Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev (2003) 2.12
Cytokines in cancer immunity and immunotherapy. Immunol Rev (2004) 2.09
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood (2003) 1.99
VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther (2007) 1.75
Use of tumour-responsive T cells as cancer treatment. Lancet (2009) 1.73
TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol (2007) 1.72
Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res (2005) 1.68
Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer (2002) 1.57
Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol (1998) 1.32
Serum tumor markers in the management of ovarian, endometrial and cervical cancer. Biomed Pharmacother (2004) 1.30
Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res (1999) 1.20
Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. Cancer Res (1991) 1.16
Cooperation of natural killer cell stimulatory factor/interleukin-12 with other stimuli in the induction of cytokines and cytotoxic cell-associated molecules in human T and NK cells. Cell Immunol (1994) 1.13
Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res (2006) 1.12
Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther (2008) 1.09
Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther (2006) 1.07
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res (2004) 1.05
IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int J Cancer (1998) 1.03
IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opin Biol Ther (2002) 1.03
E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects. Hum Gene Ther (2007) 1.02
Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol Ther (2009) 1.01
A phase I trial of recombinant gamma interferon in patients with cancer. Cancer Immunol Immunother (1985) 1.01
Interleukin 12 immunotherapy after autologous stem cell transplantation for hematological malignancies. Clin Cancer Res (2002) 0.99
Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF. Mol Ther (2011) 0.98
Sciencescope. Science (1995) 0.98
Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα. Gene Ther (2011) 0.93
Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Cancer Control (2003) 0.93
Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF. Gene Ther (2011) 0.92
The immune response to tumors. Curr Protoc Immunol (2009) 0.91
Immunologic dysfunction in cancer. Hematol Oncol Clin North Am (1996) 0.90
Mechanisms of tumor evasion. Cancer Treat Res (2005) 0.90
Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region. Cancer Gene Ther (2006) 0.89
Thymic involution and thymocyte phenotypic alterations induced by murine mammary adenocarcinomas. J Immunol (1989) 0.89
Development of gene therapy to target pancreatic cancer. Cancer Sci (2004) 0.88
Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. Cancer Immunol Immunother (2004) 0.87
Cytokine gene transfer for cancer therapy. Cytokine Growth Factor Rev (2007) 0.86
Multiple molecular and cellular changes associated with tumour stasis and regression during IL-12 therapy of a murine breast cancer model. Int J Cancer (1998) 0.85
Cationized gelatin delivery of a plasmid DNA expressing small interference RNA for VEGF inhibits murine squamous cell carcinoma. Cancer Sci (2006) 0.83
Impaired thymopoiesis occurring during the thymic involution of tumor-bearing mice is associated with a down-regulation of the antiapoptotic proteins Bcl-XL and A1. Int J Mol Med (2009) 0.79
Influence of breast cancer on thymic function in mice. J Mammary Gland Biol Neoplasia (2002) 0.77